Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Public ClinicalTrials.gov record NCT05226598. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%.
Study identification
- NCT ID
- NCT05226598
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 739 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab/Vibostolimab Biological
- Carboplatin Drug
- Cisplatin Drug
- Paclitaxel Drug
- Nab-paclitaxel Drug
- Pemetrexed Drug
- Pembrolizumab Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2022 (Actual)
- Primary completion
- Sep 24, 2024 (Actual)
- Completion
- Jan 9, 2026 (Actual)
- Last update posted
- Sep 11, 2026
2022 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCHealth Memorial Hospital-Heme Onc ( Site 0003) | Colorado Springs | Colorado | 80909 | — |
| University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0031) | Fort Collins | Colorado | 80528 | — |
| Mayo Clinic in Florida ( Site 0022) | Jacksonville | Florida | 32224 | — |
| Mount Sinai Hospital ( Site 0011) | Chicago | Illinois | 60608 | — |
| University of Chicago Medical Center ( Site 0015) | Chicago | Illinois | 60637 | — |
| New England Cancer Specialists ( Site 0008) | Scarborough | Maine | 04074 | — |
| Cancer and Hematology Centers of Western Michigan ( Site 0002) | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic in Rochester, Minnesota ( Site 0030) | Rochester | Minnesota | 55905 | — |
| Stony Brook University-Cancer Center ( Site 0013) | Stony Brook | New York | 11794 | — |
| Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0012) | Lancaster | Pennsylvania | 17604 | — |
| Charleston Oncology ( Site 0019) | Charleston | South Carolina | 29414 | — |
| University of Virginia Cancer Center ( Site 0018) | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05226598, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05226598 live on ClinicalTrials.gov.